Genome Sequencing is Critical for Forecasting Outcomes following Congenital Cardiac Surgery

W. Scott Watkins[1], Edgar J. Hernandez[2], Thomas A. Miller[3], Nathan R. Blue[4], Raquel Zimmerman[2], Eric R. Griffiths[5], Erwin Frise[6], Daniel Bernstein[7], Marko T. Boskovski[8], Martina Brueckner[9,10], Wendy K. Chung[11], J. William Gaynor[12], Bruce D. Gelb[13], Elizabeth Goldmuntz[14], Peter J. Gruber[15], Jane W. Newburger[16], Amy E. Roberts[16], Sarah U. Morton[17], John E. Mayer Jr[18] Christine E. Seidman[19,20], Jonathan G. Seidman[19], Yufeng Shen[21], Michael Wagner[22], H. Joseph Yost[23], Mark Yandell[1*], and Martin Tristani-Firouzi[24,*]

[1]Department of Human Genetics, University of Utah, Salt Lake City, UT, 84112, USA.

[2]Department of Biomedical Informatics, University of Utah, Salt Lake City, UT, 84108, USA.

[3]Department of Pediatrics, Maine Medical Center, Portland, ME, USA.

[4]Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, UT, 84112, USA.

[5]Pediatric Cardiothoracic Surgery, University of Utah, Salt Lake City, Utah, USA

[6]Fabric Genomics Inc., Oakland, CA, 94612, USA

[7]Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA 94305, USA.

[8]Department of Surgery, University of California, San Francisco, CA 94143, USA

[9]Department of Pediatrics, Yale University School of Medicine, New Haven, CT, 06416, USA.

[10]Department of Genetics, Yale University School of Medicine, New Haven, CT, 06416, USA.

[11]Departments of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.

[12]Division of Cardiothoracic Surgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA.

[13]Mindich Child Health and Development Institute and Departments of Pediatrics and Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

[14]Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

[15]Department of Surgery, Yale University, New Haven, CT, USA.

[16]Department of Cardiology, Boston Children's Hospital, and Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.

[17]Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital, Boston, MA, USA

[18]Department of Cardiovascular Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA

[19]Departments of Genetics and Medicine, Harvard Medical School, Boston 02115, USA.

[20]Howard Hughes Medical Institute, Harvard Medical School, Boston 02115, USA.

[21]Departments of Systems Biology and Biomedical Informatics, Columbia University, New York, NY 10032, USA.

[22]Division of Biomedical Informatics, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

[23]Molecular Medicine Program, University of Utah, Salt Lake City, UT 84112, USA.

[24]Nora Eccles Harrison Cardiovascular Research and Training Institute, and Division of Pediatric Cardiology, Salt Lake City, Utah, 84108, USA.

*email: scott.watkins@genetics.utah.edu, edgarh@genetics.utah.edu, Thomas.A.Miller@mainehealth.org, Nathan.Blue@hsc.utah.edu, RAQUEL.REISINGER@hsc.utah.edu, Eric.Griffiths@hsc.utah.edu, efrise@fabricgenomics.com, danb@stanford.edu, marko.boskovski@ucsf.edu, martina.brueckner@yale.edu, wendy.chung@childrens.harvard.edu, GAYNOR@chop.edu, bruce.gelb@mssm.edu, peter.gruber@yale.edu, GOLDMUNTZ@email.chop.edu, jane.newburger@cardio.chboston.org, Amy.Roberts@cardio.chboston.org, sarah.morton@childrens.harvard.edu, John.Mayer@cardio.chboston.org, cseidman@genetics.med.harvard.edu, seidman@genetics.med.harvard.edu, ys2411@columbia.edu, Michael.Wagner@cchmc.org, jyost@genetics.utah.edu, myandell@genetics.utah.edu, and Martin.Tristani@utah.edu

*Corresponding authors

Abstract

While exome and whole genome sequencing have transformed medicine by elucidating the genetic underpinnings of both rare and common complex disorders, its utility to predict clinical outcomes remains understudied. Here, we used artificial intelligence (AI) technologies to explore the predictive value of genome sequencing in forecasting clinical outcomes following surgery for congenital heart defects (CHD). We report results for a cohort of 2,253 CHD patients from the Pediatric Cardiac Genomics Consortium with a broad range of complex heart defects, pre- and post-operative clinical variables and exome sequencing. Damaging genotypes in chromatin-modifying and cilia-related genes were associated with an elevated risk of adverse post-operative outcomes, including mortality, cardiac arrest and prolonged mechanical ventilation. The impact of damaging genotypes was further amplified in the context of specific CHD phenotypes, surgical complexity and extra-cardiac anomalies. The absence of a damaging genotype in chromatin-modifying and cilia-related genes was also informative, reducing the risk for adverse postoperative outcomes. Thus, genome sequencing enriches the ability to forecast outcomes following congenital cardiac surgery.

Introduction

Congenital heart defects (CHD) represent a complex class of often life-threatening disorders that affect more than 40,000 newborns in the U.S. annually. The prevalence of CHD is approximately 1 per 100 live births, with an incidence that varies according to the specific CHD lesion[1-3]. The genetic architecture of CHD has been the focus of several large-scale sequencing efforts[4-9], demonstrating that the genetic landscape of syndromic and sporadic CHD differ, with sporadic forms characterized by considerable locus and allelic heterogeneity[7]. More recently, work by the National Heart, Lung and Blood Institute (NHLBI)-funded Pediatric Cardiac Genomics Consortium (PCGC) has shown that dominantly and recessively inherited forms of CHD have distinct genetic and phenotypic landscapes, whereby dominant forms of CHD are significantly enriched for damaging variants in chromatin-modifying genes, while recessive forms are enriched for damaging variants in cilia-related biallelic genotypes and heterotaxy phenotypes[4,5,8,9].

Recent work has also demonstrated the value of genetic testing for outcomes prediction for specific types of CHD and within specific clinical contexts[10-14]. Broader investigations, however, have faced difficulties in assaying genetic contributions across multiple CHD phenotypes and clinical contexts, in part due to the widely varying severity of CHD lesions and the complex medical and surgical interventions necessary for survival. Here, we demonstrate that condensing heterogenous CHD phenotypes into clinically relevant phenotypic categories using anatomic descriptors[15] renders these data amenable for outcomes analyses. We also show that the high allelic and locus heterogeneity characteristic of CHD can be overcome using an artificial intelligence (AI) genome interpretation tool[16], followed by categorization of damaging genotypes into molecular pathways or gene categories. This two-pronged approach of

phenotypic and genotypic classification, when combined with probabilistic graphical models, enables clinically relevant and highly personalized risk estimates in patients undergoing congenital cardiac surgery.

Results

Refining the genetic architecture of CHD. For genetic and outcomes analysis, the study population consisted of 2,253 PCGC probands (1,992 trios, 12 duos, 245 singletons) with exome sequencing, CHD phenotypes, and surgical outcomes data. The AI-based genome analysis tool GEM[16] identified putative damaging *de novo* genotypes in 238 participants (10.6% of the cohort). A total of 131 damaging *de novo*/dominant and 198 damaging recessive/biallelic genetic variants were discovered (Supplemental Tables 1, 2). There were 17 genes with damaging *de novo* variants in two or more patients. The most commonly recurrent *de novo* variants were in known CHD-related genes such as *KMT2D* (11), *CHD7* (6), *RAF1* (3), *JAG1* (3), and *TAB2* (3). Biallelic damaging genotypes were observed in multiple patients for several genes including *DYNC2H1* (3)*, DNAH5* (3), *LAMA2* (3)*, GDF1* (2), and *IFT140* (2).

We discovered that CHD phenotype categories were enriched for damaging genetic variants in specific gene pathways/categories (Table 1, Supplemental Table 3). For example, the LVO class was enriched 1.6-fold (CI 1.4-1.8) for damaging *de novo* genotypes in chromatin-modifying genes, with this signal driven primarily by patients with hypoplastic left heart syndrome (HLHS), a subset of LVO in which these genotypes showed a 1.9-fold (CI 1.3-2.5) enrichment. While previous studies implicated damaging chromatin-modifying gene variants in CHD cohorts at large[4,5,8,9], our analyses here help to define the specific CHD subtypes most influenced by damaging variants in chromatin-modification genes. The LVO phenotype class was also enriched for *de novo* genotypes in *WNT* genes (2.1-fold, CI 1.9-2.4), signal transduction genes (1.5-fold, CI 1.0-2.0), and a curated list of genes known to cause CHD (1.2-fold, CI 1.1-1.3; see Supplemental Tables 1, 2, and 3). Notably, damaging genotypes in these pathways were not enriched in HLHS patients, although an association

might be detectable with a larger sample size.

The HTX phenotype class was enriched for damaging recessive/biallelic variants in cilia-related genes (2.6-fold, CI 2.0-3.2) and showed proportionally higher enrichment in the subset of motile cilia genes modulated by *FOXJ1* (6.9-fold, 3.3-10.4), findings consistent with previous reports[5,8,17] Patients with *FOXJ1* pathway mutations accounted for four of nine HTX patients (44%) in the cilia enrichment subset. Damaged genes in the *FOXJ1* pathway were *ARMC4*, *CCDC151*, *DNAI1*, *DRC1*, *IFT172*, and *SPEF2*. The heterogenous OTHER (OTH) phenotype class was enriched for damaging *de novo* variants in chromatin-modifying genes (1.9-fold, CI 1.4-2.3) and the curated CHD genes (1.6-fold, CI 1.4-1.8). While the chromatin and CHD gene lists share 35 genes, the chromatin-modifying genes did not account for all of the association signal. For example, damaging genotypes in the curated CHD list associated with the OTH category included Noonan syndrome genes SOS1 (2), RAF1 (2), and BRAF. Consistent with previous findings, the AVC category showed an association with cilia genes but did not reach statistical significance, likely due to a low number of patients with AVC. The patients with CTD did not show a significant association with these gene lists, but our data set did not include CNVs, which are known to show association with CTD defects and tetralogy of Fallot[18].

Damaging genotypes impact surgical outcomes.

To further explore the relationships between genetic and clinical variables, we utilized Bayesian networks, a powerful statistical framework that can model complex dependencies, including non-linear relationships and indirect associations, in a probabilistic manner. In Bayesian networks, variables are depicted as nodes in a graph and conditional dependencies between variables are represented by the edges connecting those nodes. Once a network is

constructed, the impact of any combination variables on any selected outcome can be quantified, while controlling for the effects of other variables incorporated into the network. The Bayesian networks describing the conditional dependencies among damaging genotypes, CHD phenotypes and post-operative variables are shown in Figures 1a and 1b.

Damaging genotypes in chromatin-modifying and cilia-related genes (defined by a GEM[16] score ≥ 1.0) increased the probability of severe adverse clinical outcomes following congenital cardiac surgery, including mortality, cardiac arrest, and prolonged mechanical ventilation (> 7 days post-surgery). For example, damaging *de novo* chromatin genetic variants increased the probability (relative risk ratio) of mortality 1.8-fold (CI 1.5-3.2), cardiac arrest 1.7-fold (CI 1.4-2.9) and prolonged ventilation 1.6-fold (CI 1.4-2.3). Likewise, damaging recessive/biallelic cilia genotypes increased the probability of mortality 1.4-fold (CI 1.1-2.1), cardiac arrest 1.5-fold (CI 1.1-2.3) and prolonged ventilation 1.4-fold (CI 1.1-2.0). Reciprocally, in the context of these networks, the absence of a damaging genotype was associated with lower risk for these adverse post-operative outcomes, as compared to patients with a damaging genetic variant. Thus, for a proband without a damaging *de novo* chromatin genotype, the relative risk ratio for mortality was 0.55 (CI 0.31-0.69), 0.55 (CI 0.34-0.73) for cardiac arrest and 0.61 (CI 0.44-0.72) for prolonged ventilation. For a proband without a damaging recessive/biallelic cilia genotype, the relative risk ratio for mortality was 0.72 (CI 0.48-0.91), 0.63 (CI 0.43-0.88) for cardiac arrest and 0.70 (CI 0.51-0.92) for prolonged ventilation. The patient counts for the relative risk ratios presented here range from 1 to 179 (Supplemental Table 4). While the number of adverse events in some of these genetic and clinical contexts was relatively low, the Bayesian statistical framework is particularly well-suited for predictions when numbers are limiting[19,20], which was our motivation for employing this framework.

Damaging genotypes impact surgical outcomes in the context of surgical mortality risk category.

We discovered that damaging chromatin and cilia genotypes were associated with an increased risk of mortality for probands undergoing the highest risk surgical procedures. Thus, probands who died after a STAT4 or STAT5 surgical procedure were 1.8-fold (CI 1.5-4.1) more likely to harbor a damaging chromatin variant. Similarly, those who died after a STAT4 surgery were 1.7-fold (CI 1.2-2.5) more likely to harbor a damaging recessive/biallelic cilia genotype. Damaging chromatin and cilia genotypes were overrepresented in probands experiencing cardiac arrest or prolonged mechanical ventilation following the most complex surgical procedures (Figure 1c).

Damaging genotypes impact surgical outcomes in the context of CHD phenotypes

More broadly, considering mortality in the context of CHD phenotypes, LVO patients who died were 2.3-fold (CI 1.2-2.9) more likely to harbor a damaging *de novo* chromatin genotype, while HTX patients who died were 2.8-fold (CI 2.5-3.2) more likely to harbor a damaging recessive/biallelic cilia genotype. Similarly, damaging chromatin or cilia genotypes were overrepresented in probands with LVO, HLHS, and HTX who experienced cardiac arrest or prolonged post-operative ventilation (see Figure 1c). Specifically, HTX patients who arrested post-operatively were 3.3-fold (CI 1.4-5.5) more likely to harbor a damaging recessive/biallelic cilia genotype, compared to similar patients without a damaging cilia genotype. Collectively, these findings demonstrate that genome sequencing data are critical for predicting severe post-operative events in the context of specific CHD phenotypes and the

highest risk congenital heart surgeries.

Damaging genotypes impact surgical outcomes in the context of extracardiac phenotypes.

Given the recognized impact of extra cardiac anomalies (ECAs) on outcomes following congenital cardiac surgery[10,14,21], we also explored the relationship between ECAs and adverse post-operative outcomes in the context of genotypes and CHD phenotypes for 898 patients with reported ECAs (Supplemental Table 5 and 6). ECAs increased the probability (relative risk) of mortality 2.8-fold (CI 1.5-2.9) and prolonged ventilation 1.7-fold (CI 1.6-1.7) following congenital cardiac surgery. Consistent with previous findings[10], all damaging *de novo* genetic variants and *de novo* variants in chromatin-modifying genes were enriched in probands with ECAs 1.47-fold (CI 1.44-1.48) and 2.09-fold (CI 2.08-2.11), respectively. By contrast, damaging recessive/biallelic cilia genotypes were not enriched in probands with ECAs (0.8-fold; CI 0.8-1.1).

We also examined reciprocal effects, i.e., impact of predicted damaging genotypes on ECAs and adverse outcomes. For example, probands with damaging *de novo* chromatin genotypes identified by GEM were 2.5-fold (CI 2.2-5.0) more likely to have an ECA and die, compared to probands without a damaging chromatin genotype, and 2.4-fold (CI 2.0-3.4) more likely to have an ECA and prolonged ventilation (Figure 2). Moreover, a damaging recessive/biallelic cilia genotype identified by GEM increased the probability of mortality in probands with an ECA 1.5-fold (CI 1.0-2.8), compared to similar probands without a damaging cilia genotype, and increased the probability of prolonged ventilation in the presence of an ECA 1.5-fold (CI 1.1-2.5). Additionally, a damaging cilia genotype increased the probability of prolonged ventilation in HTX patients with an ECA 4.0-fold (CI 1.7-10.6), compared to similar patients without a damaging cilia genotype (see Figure 2). Taken together, these findings

demonstrate that damaging genotypes in chromatin and cilia genes increase the likelihood of severe post-operative events in the setting of ECAs.

The number of probands experiencing adverse outcomes in the AVC, CTD, and OTHER categories and harboring damaging gene pathway variants was too low to warrant generation of Bayesian networks for outcomes prediction in these CHD phenotypes. The reasons for this are multi-factorial, including genetic and phenotypic heterogeneity, low number of patients in some categories, as well as excellent surgical outcomes in these categories. For example, no patient with AVC died post-operatively in this cohort. Consequently, larger cohorts with complete genome information, including copy number and structural variation changes, are necessary to adequately predict the impact of genetics on outcomes for these CHD phenotypes. However, damaging genotypes in a number of gene pathways/categories, such as FOXJ1-controlled genes, high murine heart expression genes (HHE), WNT signaling genes, NOTCH signaling genes, and genes in a curated CHD gene list were predictive of mortality for the most complex surgical categories (Figure 3). Damaging genotypes in signal transduction and TGF-β pathways were not predictive of mortality in this data set. Taken together, these findings highlight the value of genomic data for predicting adverse outcomes following congenital cardiac surgery, especially in the context of CHD phenotypes, ECAs and surgical complexity.

Discussion

Assessing the impact of genetics on patient outcomes in CHD is complicated by the intrinsic severity of the cardiac lesion, the complex medical and surgical interventions necessary for survival, and the high degree of phenotypic, locus and allelic heterogeneity. The NHBLI-funded PCGC is one of the world's largest collections of genetic, phenotypic, and clinical variables for CHD and thus provides an excellent resource for exploring the utility of genomics data for outcomes prediction. In this study, we implemented an explainable AI-based analysis framework to automatically classify CHD patients into phenotype categories and identify damaging genetic variants and genotypes. This approach allowed us to explore how damaging genotypes impact outcomes following congenital cardiac surgery, in the context of specific CHD phenotypes, ECAs, and surgical complexity, providing risk estimates for specific clinical contexts.

Overall, the number of adverse events in probands with damaging genotypes in some clinical contexts was relatively low, despite an initial corpus of > 2000 cases. It is well established that the Bayesian statistical framework is particularly well-suited for predictions when numbers are limiting[22]; indeed, this was our motivation for employing this analytical framework. Bayesian approaches allow for the incorporation of prior knowledge, explicitly model uncertainty, and provide established best-practice methodologies to avoid overfitting. Moreover, Bayesian methods model uncertainty using a probability distribution (the posterior distribution) for each parameter rather than a single point estimate. This feature is particularly valuable in low-data scenarios, allowing the model to express uncertainty through conditional probability distributions even with limited data[23]. The confidence intervals we report were generated by simultaneously resampling the data and rebuilding the net. This is a gold standard approach for estimating uncertainty when data are limiting. In general, the wide confidence

intervals reflect this data scarcity. Taken together, these features allow Bayesian networks to make better informed predictions in low-data scenarios than do traditional frequentist approaches[22-24]. It should be noted that risk projections for some of the rare, high-risk scenarios are rough estimates. While future analyses using larger cohorts will one day refine these estimates, our results provide a necessary starting point for that future work.

De novo variants associated with CHD are enriched in genes related to chromatin regulation[4,5,8,9]. Our results identify LVO lesions and confirm HLHS as a principal driver of the chromatin signal in this cohort. HLHS is one of the most severe forms of CHD and associated with substantial morbidity and mortality. Our results show that the subset of HLHS patients with damaging genetic variants in chromatin genes has even greater risk (up to 2.6-fold) for severe post-operative outcomes in the context of the most complex surgical procedures.

Our findings also reinforce previous studies showing that damaging recessive/biallelic genotypes in cilia-related genes are overrepresented in the HTX/laterality phenotype category[5,8]. Notably, genes identified in the *FOXJ1* pathway were proportionally higher in HTX patients where four of six gene findings were supported by recessive mouse models[25] of CHD with heterotaxy (*ARMC4, CCDC151, DNAI1, DRC1*). All six of the human genes are linked to cilia dysfunction and human primary ciliary dyskinesia. Our results here demonstrate the additional utility of genetic findings for outcomes predictions. Damaging recessive/biallelic cilia genotypes increase the risk of severe adverse post-operative outcomes in the context of surgical complexity, HTX phenotype and the presence of an ECA. For example, damaging recessive/biallelic cilia genotypes substantially increase (4.01-fold) the risk of prolonged ventilation for HTX patients with an ECA. These findings are consistent

with an emerging body of literature implicating cilia dysfunction, HTX, and respiratory complications following congenital cardiac surgery[26,27].

Established and emerging literature has highlighted the impact of genetics on mortality and other adverse outcomes following congenital cardiac surgery, mostly focusing on the impact of copy number variants.[10-14] Damaging *de novo* genic variants were associated with worse transplant-free survival and longer times to final extubation in a previously reported subset of the PCGC cohort (N = 1268)[10]. Here, we expand upon these findings in the largest study to date relating genotypes to CHD surgical outcomes. Our analyses reveal that damaging genotypes in specific gene pathways/categories impact post-operative outcomes across CHD phenotypic categories in specific and quantifiable ways.

Our AI approach allowed us to unravel the conditional dependencies among diverse clinical and genetic variables and to discover their impacts, either in isolation or in combination, on post-operative outcomes. These findings define a critical role for genome sequencing in outcomes prediction for congenital cardiac surgeries, especially in the context of higher risk surgical procedures, specific CHD phenotypes and ECAs. Importantly, the absence of damaging genotypes was associated with lower predicted probability of adverse outcomes following congenital cardiac surgery as compared to those patients with damaging genotypes. Thus, genomic information is informative whether or not a proband has an identified damaging genotype.

The ability to quantify the risk of adverse outcomes allows for crucial, early deployment of potential therapeutic strategies to mitigate these risks and improve patient outcomes. For example, an extensive body of literature links ciliary dysfunction with respiratory complications, including prolonged ventilation, in the post-operative period[27-32] Pre-operative knowledge of a damaging cilia genotype would allow for early institution of

aggressive airway clearance therapy, mucolytic therapies, inhaled β2 agonists and specific ventilation strategies to promote mucociliary clearance[31]. Avoiding common anesthetic and analgesic agents that are known to impair mucociliary function may also be beneficial in these patients[32]. As turn-around times shorten and costs decline for ultra-rapid and rapid WGS, genomic data will be available in the pre-operative period to allow for risk stratification and early interventions to mitigate adverse post-operative outcomes.

Nevertheless, there are limitations inherent to this study. For example, the PCGC population is not an inception cohort and thus is likely depleted for genetic lesions that predispose to early death, meaning our morbidity estimates are likely lower bounds. Although the PCGC cohort reflects a broad spectrum of CHD, recruitment of severe CHD forms was favored, leaving us under-powered to investigate the impact of genome sequencing for less severe CHD phenotypes. Additionally, while large clinical registries, such as the STS database, are invaluable resources for outcomes research, these databases, despite the inclusion of auditing features, may suffer from data quality issues, variability in the abstraction of data, batch effects, and missing data[33-35] that might impact the interpretation of the results presented here. Finally, we acknowledge that replication in an independent, external cohort is important for reproducibility and scientific rigor. However, replication is not possible or directly comparable, as no other CHD cohorts in the world have the same depth or breadth of post-surgical variables with genomic information. The lack of comparable cohorts reflects the current constraints of the field and underscores the unique nature of the PCGC dataset. While replication in an independent cohort is not currently feasible, the relationships captured by the Bayesian network model are biologically and clinically plausible, and importantly, align with existing literature. For example, the risk of prolonged mechanical ventilation in patients with damaging cilia genotypes in the context of HTX and STAT4 surgeries is well-supported by

literature linking cilia dysfunction and HTX with post-operative respiratory complications[27-30]. As more data become available in external CHD cohorts, we plan to validate our model prospectively.

Looking to the future, a more complete description of the genetic and outcomes landscape of CHD could be enabled through clinical genome sequencing of CHD patients at even greater scales, together with initiatives by major consortia to collect and distribute genomic and clinical data more broadly. As whole genome sequencing supplants exome sequencing, and as new technologies, including long-read sequencing, reference-free whole genome assembly, and sequence analysis of somatic tissues are more broadly implemented, the diagnostic yield for CHD is likely to improve. Given the rapid decline in costs, the increasing availability and quick turn-a-round time, rapid genome sequencing is now poised to become the standard of care for all critically ill newborns.[36,37] Our findings make it clear that genome sequencing of all newborns with complex CHD will empower personalized risk-stratification for outcomes following congenital cardiac surgery.

Methods

Human subjects. All patients were diagnosed, phenotyped, and recruited by PCGC centers and participating regional hospitals into the PCGC Congenital Heart Disease Network Study (CHD GENES: ClinicalTrials.gov identifier NCT01196182; https://clinicaltrials.gov/). Informed consent was obtained from all participants or the participants' guardians. Approval for human subjects research was obtained by the institutional review boards of participating centers, including Boston's Children's Hospital, Brigham and Women's Hospital, Great Ormond Street Hospital, Children's Hospital of Los Angeles, Children's Hospital of Philadelphia, Columbia University Medical Center, Icahn School of Medicine at Mount Sinai, Rochester School of Medicine and Dentistry, Steven and Alexandra Cohen Children's Medical Center of New York, Lucile Packard Children's Hospital Stanford, University of California-San Francisco, University of Utah, and Yale School of Medicine. Automated CHD phenotype classification was performed on 14,765 PCGC participants. A subset of these participants who had both exome sequencing and perioperative data (2,253) was used for network analyses.

Clinical phenotypes. Cardiac diagnoses were obtained from review of echocardiogram, cardiac MRI, catheterization, and operative reports at the time of enrollment into the PCGC[4,5]. Detailed cardiac diagnoses for each patient were coded using the Fyler system[15]. Extra-cardiac anomalies (ECAs) were identified at the time of PCGC enrollment[4,5] (see Supplemental Tables 5 and 6). Any structural anomaly that was not acquired was classified as an extra cardiac anomaly (ECA).

Post-operative variables. For patients undergoing open heart surgery, surgical and hospitalization data were obtained from participating centers using the local data collected for

submission to the Society of Thoracic Surgeons Congenital Heart Surgery Database (STS-CHSD)[38]. A total of 59 surgical complication variables were extracted for analysis. The size of the final data set was constrained to 2,253 patients, such that all patients had WES and surgical variables had no more than 10% missing data. Most patients had multiple cardiac surgeries. A patient was scored as having an adverse event or surgical complication (e.g., prolonged mechanical ventilation) if that event occurred for any surgery at any age.

Surgical complexity. Surgical complexity is a well-known driver of mortality and morbidity. In response, the STS-European Association for Cardio-Thoracic Surgery (STAT) has created risk assessment categories in which procedures are grouped based on similar mortality rates[39]. STAT categories range from 1 to 5, with STAT1 representing the procedures with the lowest mortality rates and STAT5 representing the procedures with the highest mortality rates.

CHD classification. The PCGC has classified cardiac diagnoses for over 14,000 CHD probands using the Fyler coding system, which describes the congenitally malformed heart using a vocabulary of more than 3,000 possible phenotypic descriptors[15]. While this system allows for highly granular descriptions of heart defects, we hypothesized that condensing these terms into a few clinically relevant phenotypic categories might render them more tractable for outcomes analyses. Thus, we sought to automate cardiac phenotype classification across the entire PCGC cohort, assigning each patient to a single category. To do so, we used five major cardiac categories derived from a previous PCGC study[5]: left ventricular outflow tract obstructions (LVO), laterality and heterotaxy defects (HTX), atrioventricular canal defects (AVC), conotruncal defects (CTD), and other defects (OTH), which includes simple atrial septal defects and more complex heart defects not assigned to the other four categories[5,15]. Each participant

was assigned uniquely to one of the five phenotypic categories.

Considerable heterogeneity exists among patients' heart phenotypes and the five phenotype categories. For example, pulmonary stenosis and ventricular septal defects occur in all five phenotype categories. The observed rate of each Fyler code for each phenotype category in the 2,253 CHD analysis individuals is shown in Supplemental Table 7. This heterogeneous data structure suggested that a supervised learning model that leverages prior physician classification information[5] and weights each cardiac defect based on expert knowledge would perform better than an unsupervised classification approach. Therefore, we elected to use a gradient-boosted decision tree model trained on physician-based classification of 3,000 patients to learn the importance or information gain for each Fyler code. Once trained, the algorithm can probabilistically assign each proband to one of the five phenotype categories. In the final algorithm, Fyler codes strongly associated with a specific phenotype category in the training data greatly increase the probability that the patient belongs to a specific category. For example, tetralogy of Fallot is nearly always assigned to CTD, while hypoplastic left heart is highly predictive of LVO. In contrast, pulmonary stenosis has lower predictive value for classification.

Model learning and classification was performed using an ensemble-based method using the XGBoost library (v1.5)[40] . We created an analysis toolkit to streamline XGBoost training, grid-based parameter optimization, and performance evaluation. The truth set for training the classifier included 3,000 CHD patients, 2,752 PCGC patients previously assigned into the five CHD categories[5] and 248 randomly selected PCGC patients that were manually reviewed and assigned to a CHD phenotype category. A gradient-boosted probabilistic patient classifier was built with XGBoost[40] using Fyler terms from the 3,000 CHD patients (Supplemental Table 8). Model training was performed with five-fold cross-validation and

replacement subsampling using a grid search method to minimize mlogloss, std-mlogloss, and classification accuracy (Supplemental Figure 1a). Information gain and frequency for the top 20 Fyler codes in the model is shown in Supplemental Figure 1b. The model provides an estimate of the probability of inclusion to each of the five phenotype classes for each patient and the highest probability is used to assign each patient to a final phenotype category (Supplemental Figure 2). Model accuracy was assessed by comparing the most probable class assignment to the second-best assignment (Supplemental Figures 3a, b). Accuracy was assessed by comparing the patient's known phenotype category, derived from expert knowledge[5], to the patient's predicted phenotype category label (Supplemental Table 9). Single-class prediction accuracy for the training data was higher for HTX (98.9%), AVC (97.8%), and LVO (97.7%) than for CTD (95.3%) and OTH (91.9%), where a low level of ambiguity occurred. Overall classification accuracy was 97.7% with a specificity of 99.3%, and sensitivity of 97.7% (Supplemental Table 10). We then applied the trained classifier to 14,765 PCGC CHD patients with Fyler descriptors to assign each patient to one of the five phenotype categories (Supplemental Table 11). Final classification of the 3,000 training patients was identical to the original training predictions. The five phenotype categories remained generally proportional between the training data and the full data set, with a maximum observed difference of 4.2% for CTD patients.

AI-based scoring of predicted damaging genetic variants. All CHD patients were sequenced using exome capture (Agilent, Illumina) and sequenced on Illumina sequencing platforms using 100 bp paired-end reads. Read data was aligned using the human reference genome (GRCh37) and then genotyped with GATK / Sentieon using best practice recommendations to produce a joint-called VCF file with all probands and their parents if

available. AI-based identification of candidate disease-causing genotypes was performed using Fabric GEM[16,41-44] (Fabric Genomics, Oakland, CA). GEM evaluates all genotypes present in a VCF file for a patient. GEM incorporates Human Phenotype Ontology (HPO) terms, sex, genotype frequency (gnomAD), evolutionary conservation, Online Mendelian Inheritance in Man (OMIM), gnomAD, and ClinVar information and parental genotypes in a probabilistic AI framework to identify the most likely genetic variant or genotype that explains the patient's disease phenotype. HPO terms utilized in the GEM analyses were based on each patient's Fyler phenotypes, which were mapped to HPO terms using the Clinithink software package (Clinithink, London). Because GEM is phenotype aware, reported genes have some support in the literature for association with the proband's particular CHD phenotype. However, we cannot exclude the possibility that in some cases, the reported damaging genotype is incidental to CHD etiology; however, the high score threshold used for these analyses (>1), means that there was strong phenotypic support for the genotype, and/or the variant(s) involved have strong ClinVar associations with pathogenicity. Because WES are difficult substrates for copy number variant (CNV) calling, we restricted our analyses to SNVs and short indels.

GEM's gene scores are $\log_{10}$ transformed Bayes factors[45] that summarize the relative support for the hypothesis that the prioritized genotype damages the gene in which it resides and explains the patient's phenotype versus the hypothesis that the variant neither damages the gene nor explains the patient's phenotype. We used a stringent GEM score of ≥ 1.0 to represent a likely pathogenic genotype. A recent genomic analysis of critically ill newborns showed that a GEM score of ≥ 1.0 identified 90% of all true positive damaging variants, with a median of two candidate variants per patient[16]. Gene penetrance for GEM calculations was set to 0.95 to enforce strict consideration of known dominant and recessive disorders. For downstream analyses, damaging genetic variants were classified as *de novo*, dominant, or

recessive/biallelic variants based on their inheritance pattern in trios. Dominant and *de novo* damaging variants were required to have a frequency of < 1/10000 in gnomAD databases (v2.1, v3.1) and most of these variants were not observed in gnomAD. Overall, we identified damaging *de novo* or recessive genotypes in 10.56% of the study cohort (see Supplemental Tables 1, 2), in line with previous studies that utilized different methods of defining pathogenicity[4,5,8,9]. Damaging genetic variants were assigned to several functional gene pathways. The CHD gene list represents genes from the literature known to directly cause or be associated with CHD and has been previously described[8]. The CHD gene list contains 35 genes in the chromatin list, but no genes from the cilia gene lists and represents a diverse set of genes not specific to a single pathway. Gene lists for all other gene pathways were obtained using the reactome pathway browser (see Supplemental Table 3) and have been previously described[5,8,9] There is some overlap between gene lists, with some genes represented in more than one gene pathway/category (Supplemental Figure 4).

Probabilistic graphical models. Probabilistic graphical models (PGMs) provide a robust explainable AI methodology capable of discovering and quantifying additive and synergistic effects amongst broad classes of variables. For the work presented here, we used a form of PGMs known as a Bayesian networks[46]. Bayesian networks are fully transparent, and their graphical representation offers an intuitive, visual, and qualitative mechanism for understanding the probabilistic dependencies among variables and the impacts of multiple variables on outcomes of interest[47-54]. Moreover, Bayesian networks offer practical advantages over regression approaches, by capturing the entire joint probability distribution of the data, quantitatively encompassing all interrelationships among the variables incorporated in the non-linear model. Thus, a single network can be used to explore any combination of variables as a

target outcome in one query and then as a risk factor for a different target outcome, all within the same model. For more on these points see [46,55,56].

Feature selection. Single variables, such as damaging genetic variants in chromatin-modifying genes, were tested for conditional dependency with phenotype variables using exact Bayesian networks. Each conditional probability (e.g., the probability of LVO given a damaging *de novo* chromatin variant: $P(\text{LVO} \mid c\square romatin\ dGV)$) was estimated as the median conditional probability from 1000 independent networks. Conditional probability estimates were divided by the baseline probability for each respective phenotype to obtain absolute risk ratios. Associations with absolute risk ratios ≥ 1.0 were selected for further analyses. Surgery-related variables associated with gene categories and CHD phenotypes were identified in a similar way. Each surgical feature was tested individually as a conditional variable with genetic variables and each of the five specific CHD phenotypes.

Network construction. Bayesian networks were created for each CHD phenotype category. Each network included genetic and surgical variables identified in the feature selection stage above. Genetic, phenotypic, and surgical variables included or excluded for the networks and their baseline frequencies are listed in Supplemental Table 12. Final network variables are shown in Supplemental Table 13. All-cause mortality was included in each network. All input conditional variables were coded as presence/absence. A small number of missing surgical values (< 10% for any single variable) was imputed using a K-nearest neighbors approach (k = 10). Because highly correlated variables may influence Bayesian network structure learning and risk estimation, variables included in the networks were screened for colinear and multicollinear states by correlation analysis (Supplemental Figures 5a, b). Final network

variables were not colinear and pairwise correlations were between -0.11 and 0.30, except for LVO and HLHS. The structure of each network was learned with the Silander-Myllymaki exact algorithm with Bayesian information criterion (BIC) scoring[57]. Posterior probabilities were network propagated using exact inference. The accuracy of network inferred risk estimates can be affected by sample size. Many studies advocate Bayesian analysis for low sample size applications[19,20,22-24,58]. With low sample sizes, accurate posterior probabilities and risk estimates are highly dependent on unbiased prior probability estimates. Our initial probability estimates for variables used in the study are based on 2,253 CHD patients from multiple surgical sites and are, therefore, likely to be representative probability estimates for a critical CHD surgical cohort and without strong biases. Network structure learning and belief propagation were performed with the bnstruct and gRain R packages[59,60]. To improve convenience and functionality, we created the BayesNetExplorer.jl package which implements network structure learning and belief propagation methods and provides tools for feature selection, risk estimation, graphics, and other network analysis tasks.

Risk Calculations. We used two risk ratios (RR) to summarize our risk estimates, absolute RR and relative RR. For example, the absolute RR of a LVO phenotype given a damaging genotype in a chromatin-modifying gene is as follows: $Absolute\ RR_{LVO|dGVchromatin} = \frac{P(LVO\ =\ true\ |\ dGV\ chromatin=true\ )}{P(LVO\ =\ true)}$ which estimates the probability of LVO given a damaging mutation in chromatin-modifying genes compared to the marginal probability of LVO in the entire population. The relative RR estimates the relative change in mortality risk for LVO patients with damaging mutations in chromatin-modifying genes, compared to similar patients without a damaging chromatin genotype: $Relative\ RR_{mortality\ +\ LVO\ |\ dGV\ chromatin} =$

$$\frac{P(mortality = true, LVO = true \mid dGV\ chromatin = true\ )}{P(mortality = true, LVO = true \mid dGV\ chromatin = false\ )}.$$ Final risk ratios and their confidence

intervals are reported as the median and 95% confidence interval from an empirical distribution of risk

ratio estimates. The empirical distributions were created by randomly resampling the data set with

replacement and recreating 1000 independent networks and their risk estimates. A correction

factor (k=1/N) or a network smoothing value (0.01) was used to prevent zero-state probability

estimates during bootstrapping.

Data availability

Genetic and phenotypic data used in the paper are provided in the supplementary tables. Exome sequencing data have been deposited in the database of Genotypes and Phenotypes (dbGaP) under accession numbers phs000571.v1.p1, phs000571.v2.p1 and phs000571.v3.p2. GEM is a commercial tool for AI-assisted clinical interpretation of WES and WGS. It has been licensed by University of Utah Hospitals from Fabric Genomics Inc. and is used by Utah faculty, staff, and affiliates for WGS analyses campus wide. Additional licensing information is available from Fabric Genomics Inc. Additional data for individuals is available through the HeartsMart database: https://heartsmart.pcgcid.org/.

Code availability

Code and software packages used in the analyses are available from the following resources: https://github.com/dmlc/XGBoost.jl , https://github.com/ScottWatkins/BayesNetExplorer, https://julialang.org/, https://www.r-project.org/, and https://reactome.org .

References

1.   Hoffman, J.I. & Kaplan, S. The incidence of congenital heart disease. *J Am Coll Cardiol* **39**, 1890-1900 (2002).
2.   Liu, Y.*, et al.* Global birth prevalence of congenital heart defects 1970-2017: updated systematic review and meta-analysis of 260 studies. *Int J Epidemiol* **48**, 455-463 (2019).
3.   Reller, M.D., Strickland, M.J., Riehle-Colarusso, T., Mahle, W.T. & Correa, A. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. *J Pediatr* **153**, 807-813 (2008).
4.   Homsy, J.*, et al. De novo* mutations in congenital heart disease with neurodevelopmental and other congenital anomalies. *Science* **350**, 1262-1266 (2015).
5.   Jin, S.C.*, et al.* Contribution of rare inherited and *de novo* variants in 2,871 congenital heart disease probands. *Nat Genet* **49**, 1593-1601 (2017).
6.   Richter, F.*, et al.* Genomic analyses implicate noncoding de novo variants in congenital heart disease. *Nat Genet* **52**, 769-777 (2020).
7.   Sifrim, A.*, et al.* Distinct genetic architectures for syndromic and nonsyndromic congenital heart defects identified by exome sequencing. *Nat Genet* **48**, 1060-1065 (2016).
8.   Watkins, W.S.*, et al.* De novo and recessive forms of congenital heart disease have distinct genetic and phenotypic landscapes. *Nat Commun* **10**, 4722 (2019).
9.   Zaidi, S.*, et al. De novo* mutations in histone-modifying genes in congenital heart disease. *Nature* **498**, 220-223 (2013).
10.   Boskovski, M.T.*, et al.* De Novo Damaging Variants, Clinical Phenotypes, and Post-Operative Outcomes in Congenital Heart Disease. *Circ Genom Precis Med* **13**, e002836 (2020).
11.   Carey, A.S.*, et al.* Effect of copy number variants on outcomes for infants with single ventricle heart defects. *Circ Cardiovasc Genet* **6**, 444-451 (2013).
12.   Geddes, G.C., Przybylowski, L.F., 3rd & Ware, S.M. Variants of significance: medical genetics and surgical outcomes in congenital heart disease. *Curr Opin Pediatr* **32**, 730-738 (2020).
13.   Kim, D.S.*, et al.* Burden of potentially pathologic copy number variants is higher in children with isolated congenital heart disease and significantly impairs covariate-adjusted transplant-free survival. *J Thorac Cardiovasc Surg* **151**, 1147-1151 e1144 (2016).
14.   Landis, B.J.*, et al.* Learning to Crawl: Determining the Role of Genetic Abnormalities on Postoperative Outcomes in Congenital Heart Disease. *J Am Heart Assoc* **11**, e026369 (2022).
15.   Newburger, J.W., Fyler, J. & Colan, S.D. Donald Charles Fyler: 1924-2011. *Cardiol Young* **21**, 485-489 (2011).
16.   De La Vega, F.M.*, et al.* Artificial intelligence enables comprehensive genome interpretation and nomination of candidate diagnoses for rare genetic diseases. *Genome Med* **13**, 153 (2021).
17.   Burnicka-Turek, O.*, et al.* Cilia gene mutations cause atrioventricular septal defects by multiple mechanisms. *Human molecular genetics* **25**, 3011-3028 (2016).
18.   Goldmuntz, E.*, et al.* Frequency of 22q11 deletions in patients with conotruncal defects. *J Am Coll Cardiol* **32**, 492-498 (1998).
19.   Lee, S.Y. & Song, X.Y. Evaluation of the Bayesian and Maximum Likelihood

Approaches in Analyzing Structural Equation Models with Small Sample Sizes. *Multivariate Behav Res* **39**, 653-686 (2004).

20. McNeish, D. On Using Bayesian Methods to Address Small Sample Problems. *Structural Equation Modeling-a Multidisciplinary Journal* **23**, 750-773 (2016).

21. Vodiskar, J.*, et al.* Impact of Extracardiac Anomalies on Mortality and Morbidity in Staged Single Ventricle Palliation. *Ann Thorac Surg* **115**, 1197-1204 (2023).

22. Carlin, B.P. & Louis, T.A. *Bayesian Methods for Data Analysis, Third Edition*, (Chapman and Hall/CRC, 2008).

23. Kruschke, J.K. & Liddell, T.M. The Bayesian New Statistics: Hypothesis testing, estimation, meta-analysis, and power analysis from a Bayesian perspective. *Psychonomic Bulletin & Review* **25**, 178-206 (2018).

24. Gelman, A.*, et al. Bayesian Data Analysis, 3rd edition*, (CRC Press, 2013).

25. Li, Y.*, et al.* Global genetic analysis in mice unveils central role for cilia in congenital heart disease. *Nature* **521**, 520-524 (2015).

26. Garrod, A.S.*, et al.* Airway ciliary dysfunction and sinopulmonary symptoms in patients with congenital heart disease. *Ann Am Thorac Soc* **11**, 1426-1432 (2014).

27. Nakhleh, N.*, et al.* High prevalence of respiratory ciliary dysfunction in congenital heart disease patients with heterotaxy. *Circulation* **125**, 2232-2242 (2012).

28. Harden, B.*, et al.* Increased postoperative respiratory complications in heterotaxy congenital heart disease patients with respiratory ciliary dysfunction. *J Thorac Cardiovasc Surg* **147**, 1291-1298 e1292 (2014).

29. Stewart, E.*, et al.* Airway ciliary dysfunction: Association with adverse postoperative outcomes in nonheterotaxy congenital heart disease patients. *J Thorac Cardiovasc Surg* **155**, 755-763 e757 (2018).

30. Swisher, M.*, et al.* Increased postoperative and respiratory complications in patients with congenital heart disease associated with heterotaxy. *J Thorac Cardiovasc Surg* **141**, 637-644, 644 e631-633 (2011).

31. Goetz, R.L., Vijaykumar, K. & Solomon, G.M. Mucus Clearance Strategies in Mechanically Ventilated Patients. *Front Physiol* **13**, 834716 (2022).

32. Feldman, K.S.*, et al.* Differential effect of anesthetics on mucociliary clearance in vivo in mice. *Sci Rep* **11**, 4896 (2021).

33. Kim, K.M.*, et al.* The Society of Thoracic Surgeons Adult Cardiac Surgery Database: 2022 Update on Outcomes and Research. *Ann Thorac Surg* **115**, 566-574 (2023).

34. Jacobs, J.P.*, et al.* Successful linking of the Society of Thoracic Surgeons Database to Social Security data to examine the accuracy of Society of Thoracic Surgeons mortality data. *J Thorac Cardiovasc Surg* **145**, 976-983 (2013).

35. Brown, M.L., Lenoch, J.R. & Schaff, H.V. Variability in data: the Society of Thoracic Surgeons National Adult Cardiac Surgery Database. *J Thorac Cardiovasc Surg* **140**, 267-273 (2010).

36. Dimmock, D.*, et al.* Project Baby Bear: Rapid precision care incorporating rWGS in 5 California children's hospitals demonstrates improved clinical outcomes and reduced costs of care. *American journal of human genetics* **108**, 1231-1238 (2021).

37. Group, N.I.S.*, et al.* Effect of Whole-Genome Sequencing on the Clinical Management of Acutely Ill Infants With Suspected Genetic Disease: A Randomized Clinical Trial. *JAMA Pediatr* **175**, 1218-1226 (2021).

38. Nathan, M.*, et al.* Completeness and Accuracy of Local Clinical Registry Data for Children Undergoing Heart Surgery. *Ann Thorac Surg* **103**, 629-636 (2017).

39. Jacobs, M.L.*, et al.* Updating an Empirically Based Tool for Analyzing Congenital Heart

Surgery Mortality. *World J Pediatr Congenit Heart Surg* **12**, 246-281 (2021).

40. Chen, T. & Guestrin, C. XGBoost: A Scalable Tree Boosting System. in *Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining* (Association for Computing Machinery, San Francisco, California, USA, 2016).

41. Kingsmore, S.F.*, et al.* A genome sequencing system for universal newborn screening, diagnosis, and precision medicine for severe genetic diseases. *American journal of human genetics* **109**, 1605-1619 (2022).

42. Nyaga, D.M.*, et al.* Benchmarking and quality control for nanopore sequencing and feasibility of rapid genomics in New Zealand: validation phase at a single quaternary hospital. *medRxiv*, 2024.2006.2013.24307636 (2024).

43. Ye, G.X., Ontiveros, E., Ivander, A., Velinov, M. & Simotas, C. Autosomal Recessive Infantile Hyaline Fibromatosis Identified Using Artificial Intelligence-Assisted Rapid Whole Genome Sequencing: A Rare, Multisystemic, Hereditary Disorder. *Cureus* **16**, e62037 (2024).

44. Miller, T.A.*, et al.* Genetic and clinical variables act synergistically to impact neurodevelopmental outcomes in children with single ventricle heart disease. *Commun Med (Lond)* **3**, 127 (2023).

45. Goodman, S.N. Toward evidence-based medical statistics. 2: The Bayes factor. *Ann Intern Med* **130**, 1005-1013 (1999).

46. Pearl, J. *Causality : models, reasoning, and inference*, (Cambridge University Press, Cambridge, U.K. ; New York, 2000).

47. Amann, J.*, et al.* Explainability for artificial intelligence in healthcare: a multidisciplinary perspective. *BMC Med Inform Decis Mak* **20**, 310 (2020).

48. Franz L SY & B., P. A deep learning pipeline for patient diagnosis prediction using electronic health records. *arXiv preprint* (2020).

49. Heckerman, D., Geiger, D. & Chickering, D.M. Learning Bayesian Networks: The Combination of Knowledge and Statistical Data. *arXiv preprint* (2013).

50. London, A.J. Artificial Intelligence and Black-Box Medical Decisions: Accuracy versus Explainability. *Hastings Cent Rep* **49**, 15-21 (2019).

51. Miotto, R., Li, L., Kidd, B.A. & Dudley, J.T. Deep Patient: An Unsupervised Representation to Predict the Future of Patients from the Electronic Health Records. *Sci Rep* **6**, 26094 (2016).

52. Payrovnaziri, S.N.*, et al.* Explainable artificial intelligence models using real-world electronic health record data: a systematic scoping review. *J Am Med Inform Assoc* **27**, 1173-1185 (2020).

53. Rajkomar, A.*, et al.* Scalable and accurate deep learning with electronic health records. *NPJ Digit Med* **1**, 18 (2018).

54. Wang, H.*, et al.* Predicting Hospital Readmission via Cost-Sensitive Deep Learning. *IEEE/ACM Trans Comput Biol Bioinform* **15**, 1968-1978 (2018).

55. Miller, T.A.*, et al.* Genetic, demographic and clinical variables act synergistically to impact neurodevelopmental outcomes in children with single ventricle heart disease. *medRxiv*, 2022.2010.2001.22280594 (2023).

56. Wesolowski, S.*, et al.* An explainable artificial intelligence approach for predicting cardiovascular outcomes using electronic health records. *PLOS Digit Health* **1**(2022).

57. Silander, T. & Myllym¨aki, P. A Simple Approach for Finding the Globally Optimal Bayesian Network Structure. *arXiv* **1206.6875** (2012).

58. van de Schoot, R.*, et al.* A gentle introduction to bayesian analysis: applications to developmental research. *Child Dev* **85**, 842-860 (2014).

59.   Franzin, A., Sambo, F. & Di Camillo, B. bnstruct: an R package for Bayesian Network structure learning in the presence of missing data. *Bioinformatics* **33**, 1250-1252 (2017).

60.   Hojsgaard, S. Graphical Independence Networks with the gRain Package for R. *J Stat Softw* **46**, 1-26 (2012).

Acknowledgments

We thank the patients and their families for participating in the Pediatric Cardiac Genomics Consortium and Bench to Bassinet research programs. This research would not be possible without the clinical professionals involved in patient recruitment, and we thank those at the following institutions including the Columbia Medical School: D. Awad, C. Breton, K. Celia, C. Duarte, D. Etwaru, N. Fishman, E. Griffin, M. Kaspakoval, J. Kline, R. Korsin, A. Lanz, E. Marquez, D. Queen, A. Rodriguez, J. Rose, J.K. Sond, D. Warburton, A. Wilpers, and R. Yee; 2) the Children's Hospital of Los Angeles: J. Ellashek and N. Tran; 3) the Children's Hospital of Philadelphia: S. Edman, J. Garbarini, J. Tusi, and S. Woyciechowski; 4) the Harvard Medical School: J. Geva and M. Borensztein; 5) the Icahn School of Medicine at Mount Sinai: A. Julian, M. Mac Neal, Y. Mendez, T. Mendiz-Ramdeen, and C. Mintz; 6) the University College London: B. McDonough, K. Flack, L. Panesar, and N. Taylor; 7) the University of Rochester School of Medicine and Dentistry: E. Taillie; and 8) the Yale School of Medicine: N. Cross. We thank Nick Felicelli, Prakash Velayutham, and the staff at the Cincinnati Children's Hospital Medical Center for computational support and for providing access to the HeartsMart database. We thank Carson Holt, Shawn Rynearson, Barry Moore at the Utah Center for Genomic Discovery and the staff at the Utah Center for High Performance Computing for high-throughput processing of patient sequence data.

The Pediatric Cardiac Genomics Consortium (PCGC) program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through grants UM1HL128711, UM1HL098162, UM1HL098147, UM1HL098123, UM1HL128761, U01-HL098153, U01-HL098163, and U01HL131003. This manuscript was prepared in collaboration with investigators of the PCGC and has been reviewed and/or approved by the PCGC. PCGC investigators are listed at [https://benchtobassinet.com/?page_id=119]

Author contributions

W.S.W., E.J.H., M.Y., and M.T.F. conceived and planned the project; M.T.F. and W.S.W. analyzed the data and created the manuscript; E.J.H., R.Z., advised the network analysis and presentation; T.A.M. provided clinical interpretation and analysis support; E.F. contributed to the GEM implementation; M.T.F. and M.Y. oversaw all aspects of the network and statistical analyses; M.W. provided network access to data; W.S.W., E.J.H., T.A.M., R.Z., D.B., M.B., W.K.C., J.W.G., B.D.G., E.G., P.G., J.W.N., S.U.M., A.E.R., C.E.S., J.G.S., Y.S., H.J.Y., N.R.B., E.R.G., M.T.B, J.E.M., M.Y., and M.T.F. edited the final manuscript.

Competing interests

The authors declare the following competing interests: M.Y. -- GEM commercialization through Fabric Genomics, Inc; E.F. is an employee of Fabric Genomics.

Table 1. Absolute risk ratios for CHD phenotypes by gene pathway

Gene pathway	N	Cardiac phenotype				
		AVC (N=64)	CTD (N=934)	HTX (N=219)	LVO (N=647)	OTH (N=389)
Chromatin genes (*de novo*)	28	-	0.52 (0.32, 0.72)	-	**1.61** (1.41, 1.81)	**1.85** (1.44, 2.26)
Cilia genes (*recessive*)	35	3.02 (0.00, 6.97)	0.55 (0.41, 0.69)	**2.63** (2.06, 3.20)	1.09 (0.90, 1.28)	0.67 (0.18, 1.16)
HHE genes (*de novo*)	9	-	0.82 (0.00, 1.74)	1.58 (0.00, 9.05)	0.84 (0.00, 4.88)	1.93 (0.00, 4.29)
Wnt genes (*de novo*)	18	-	0.54 (0.16, 0.92)	-	**2.13** (1.86, 2.40)	0.99 (0.00, 2.25)
FoxJ1 genes (*recessive*)	6	-	0.56 (0.00, 3.54)	**6.89** (3.30, 10.36)	0.78 (0.00, 4.82)	0.81 (0.00, 3.54)
Notch1 genes (*de novo*)	8	-	1.49 (0.96, 2.02)	-	1.36 (0.00, 2.86)	-
Signal trans genes (*de novo*)	14	3.56 (0.00, 20.50)	0.69 (0.24, 1.14)	-	**1.51** (1.01, 2.01)	1.26 (0.00, 2.84)
TGF-β genes (*de novo*)	13	-	1.11 (0.74, 1.48)	-	1.09 (0.32, 1.86)	1.37 (0.00, 3.05)
CHD genes (*de novo*)	51	-	0.86 (0.78, 0.94)	0.27 (0.00, 1.43)	**1.22** (1.11, 1.33)	**1.59** (1.38, 1.80)

Each ratio is reported as the mean and 95% confidence interval from 1,000 bootstrap replicates fitted to a t-distribution. Absolute risk ratios with 95% CIs > 1.00 are bolded. The column labeled N indicates the number of patients with damaging genetic variants/genotypes (GEM score ≥ 1) found in that gene pathway. The total number of patients in each CHD category is listed in the column heading. Dashes indicate no patients with damaging genotypes. Phenotype categories are atrioventricular canal defects (AVC), conotruncal defects (CTD), heterotaxy/laterality defects (HTX), left ventricular outflow tract obstructions (LVO), and all other defects (OTH). Additional abbreviations: HHE, high heart expression genes in the developing mouse heart; CHD genes, a curated list of genes previously reported to cause CHD (see also Supplemental Table 3).

Figure 1. Damaging chromatin and cilia genotypes predict adverse post-operative outcomes in the context of CHD phenotypes and surgical complexity.

Figure 2. Damaging chromatin and cilia genotypes predict adverse post-operative outcomes in the context of extracardiac anomalies.

Figure 3. Damaging genotypes in various gene categories/pathways are predictive of mortality for the most complex surgical procedures.

Figure legends

Figure 1. Damaging chromatin and cilia genotypes predict adverse post-operative outcomes in the context of CHD phenotypes and surgical complexity. Bayesian networks display a best machine-learned relationship among genotypes, phenotypes, and outcomes for 2,253 surgical patients with CHD. Each network node represents a present/absent variable. Damaging genotypes in chromatin-modifying genes (CHRMdGV) or cilia-related genes (CILIAdGV) were identified from the exomes of 2,253 CHD patients by GEM. Phenotype classes were predicted from Fyler codes using XGBoost. Surgical outcomes for each patient were obtained from the Society of Thoracic Surgeons national database. Relative risks for selected surgical outcomes were then estimated from each network using network-propagated probabilities. **a,** An exact Bayesian network depicting the relationship among damaging *de novo* genetic variants in chromatin-modifying genes (green), phenotypes: LVO, HLHS, and ECAs (blue), surgical STAT4 or STAT5 category (yellow), and surgical outcomes (orange). **b,** An exact Bayesian network depicting the relationship among damaging recessive genetic variants in cilia-related genes (green), phenotypes: laterality defects (HTX) and extra cardiac anomalies (ECAs) (blue), surgical STAT4 category (yellow), and surgical outcomes: long ventilation time, cardiac arrest, and mortality (orange). Directed acyclic graphs were moralized and displayed as non-directional networks. **c,** Relative risk ratios for adverse post-operative outcomes and CHD phenotypes or surgical complexity, comparing probands with and without damaging genotypes. Empirical ninety-five percent confidence intervals (CI 5, 95) are based on 1,000 resampled network-based probabilities (see Methods). Abbreviations: Chromatin dGV: *de novo* damaging genotypes in chromatin-modifying genes, LVO: left ventricular outflow tract obstruction, HLHS: hypoplastic left heart syndrome Cilia dGV: biallelic damaging genotypes in cilia-related genes, ECA: extra cardiac anomaly, HTX: heterotaxy/laterality defects, MORT: mortality, STAT4:

surgical STAT4 category, STAT4-5: surgical STAT 4 or STAT5 category, VENT: post-operative ventilation time >7 days. For Figures 1c, 2, and 3, there were 8 – 35 patients in the conditional subsets and 1 – 5 patients in the target sets (see Supplemental Table 13).

Figure 2. Damaging chromatin and cilia genotypes predict adverse post-operative outcomes in the context of extracardiac anomalies. Relative risk ratios for adverse post-operative outcomes and extracardiac anomalies (ECAs), comparing probands with and without damaging genotypes in chromatin-modifying or cilia-related genes. The \\ symbol represents CI95 that exceeds the x-axis range. Target and conditional counts are listed in Supplemental Table 4.

Figure 3. Damaging genotypes in various gene categories/pathways are predictive of mortality for the most complex surgical procedures. Relative risk ratios for adverse post-operative outcomes and surgical complexity, comparing probands with and without damaging genotypes in various gene pathways or categories. Gene lists are described in Supplemental Table 3 and have been previously published.[5,8,9] There is overlap between gene lists, with some genes represented in more than one gene pathway/category (Supplemental Figure 4). Target and conditional counts are listed in Supplemental Table 4.